Group One Trading
RPRX icon

Group One Trading’s Royalty Pharma RPRX Stock Holding History

Group One Trading’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.22M Buy
87,900
+75,600
+615% +$3.31M 0.01% 1435
2025
Q4 		$475K Sell
12,300
-40,200
-77% -$1.53M ﹤0.01% 3568
2025
Q3 		$1.85M Sell
52,500
-108,900
-67% -$3.94M ﹤0.01% 2400
2025
Q2 		$5.82M Sell
161,400
-45,400
-22% -$1.5M 0.01% 1214
2025
Q1 		$6.44M Buy
206,800
+109,500
+113% +$3.47M 0.02% 894
2024
Q4 		$2.48M Buy
97,300
+45,000
+86% +$1.19M 0.01% 1725
2024
Q3 		$1.48M Buy
52,300
+15,400
+42% +$427K ﹤0.01% 1977
2024
Q2 		$973K Sell
36,900
-115,700
-76% -$3.21M ﹤0.01% 1999
2024
Q1 		$4.63M Buy
152,600
+42,300
+38% +$1.25M 0.02% 876
2023
Q4 		$3.1M Sell
110,300
-40,500
-27% -$1.11M 0.01% 1498
2023
Q3 		$4.09M Buy
150,800
+76,200
+102% +$2.26M 0.01% 1073
2023
Q2 		$2.29M Sell
74,600
-2,600
-3% -$88.1K 0.01% 1576
2023
Q1 		$2.78M Buy
77,200
+41,300
+115% +$1.53M 0.01% 1260
2022
Q4 		$1.42M Buy
35,900
+7,700
+27% +$321K ﹤0.01% 2124
2022
Q3 		$1.13M Buy
28,200
+23,800
+541% +$1.02M ﹤0.01% 2443
2022
Q2 		$185K Sell
4,400
-1,700
-28% -$69.7K ﹤0.01% 4381
2022
Q1 		$238K Sell
6,100
-17,400
-74% -$683K ﹤0.01% 4614
2021
Q4 		$936K Sell
23,500
-2,200
-9% -$85.5K ﹤0.01% 3426
2021
Q3 		$929K Buy
25,700
+15,100
+142% +$587K ﹤0.01% 3496
2021
Q2 		$434K Sell
10,600
-2,100
-17% -$89.3K ﹤0.01% 4372
2021
Q1 		$554K Buy
12,700
+7,400
+140% +$351K ﹤0.01% 3915
2020
Q4 		$265K Buy
5,300
+4,000
+308% +$170K ﹤0.01% 3849
2020
Q3 		$55K Buy
+1,300
New +$55.8K ﹤0.01% 4592

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Group One Trading's RPRX Position: Q1 2026 in Review

Group One Trading sold out of Royalty Pharma (RPRX) in Q1 2026, closing a stake of 10,093 shares — an estimated $442K sold.

Group One Trading first reported a position in RPRX in Q1 2021 and held it in 3 quarters. The position peaked at $390K in Q4 2025. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Group One Trading reported no remaining Royalty Pharma position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 10,093 Royalty Pharma shares in Q1 2026, an estimated $442K.
  • Group One Trading first reported a position in Royalty Pharma in Q1 2021 and held it in 3 quarters.
  • Group One Trading's Royalty Pharma position peaked at $390K in Q4 2025.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.